Yamanouchi to launch prostate cancer drug Eligard

pharmafile | December 30, 2004 | News story | Sales and Marketing |   

A new treatment for advanced prostate cancer, Eligard, has received approval in 24 European countries and will be marketed by Yamanouchi, who have entered a marketing agreement with US-based developers QLT and German-US biotech MediGene.

Eligard depot is a member of the luteinizing hormone-releasing hormone agonists class, (LHRH agonists) and works by lowering the levels of testosterone in the body, which may in turn reduce the symptoms related to the disease.

MediGene received marketing authorisation for the drug in its home market of Germany over a year ago but waited until it sealed a marketing agreement with Yamanouchi before launching the drug there in May 2004.